AggregoTV - NSCLC

AggregoTV - NSCLC

No One Missed—NSCLC Biomarker Testing

Dr Jorge Gomez and Andrea Ferris discuss "No One Missed", a new campaign to raise awareness about comprehensive biomarker testing which can reveal vital information that can help identify the appropriate treatment...

Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC

Dr Patrick Y. Wen discusses adjuvant osimertinib in resected EGFR-Mutated NSCLC.

Novel Therapies on the Horizon for Lung Cancer

Dr Samreen Ahmed discusses novel therapies for lung cancer such as those targeting KRAS mutations and antibody-drug conjugates for the treatment of HER2-driven non-small cell lung cancer.


Multisystem Immune-Related AEs With Immunotherapy in NSCLC

Jarushka Naidoo gives an overview of a study investigating immune-related adverse events associated with immune checkpoint inhibitor therapy for the treatment of NSCLC.

NERO Trial: PARP Inhibitors for Chemosensitive NSCLC

Dr Dean Fennell shares an update on the randomized Phase II/III NERO study investigating PARP inhibitors in patients with NSCLC who have previously responded to chemotherapy.

Antibiotics Impact Outcomes With Pembrolizumab in NSCLC Patients

Dr David Pinato outlines the impact of host determinants on response to immunotherapy in patients with NSCLC, highlighting PD-L1 expression as a biomarker for pembrolizumab response.

Guideline-Recommended Molecular Testing in Early-Stage NSCLC

This is a multidisciplinary look at molecular testing in early-stage non-small cell lung cancer.

Using Clinical Trials to Drive Treatment Approaches in Lung Cancer

Dr Andrew Robinson discusses the importance of using clinical trials to drive treatment approaches and summarizes the role of immunotherapies in the treatment of squamous NSCLC...

Systemic Treatment of Non-Oncogene Addicted NSCLC With Brain Metastases

Dr Lizza Hendriks discusses the systemic treatment of patients with non-small cell lung cancer and brain metastases who are non-oncogene addicted.

What Are The Symptoms of NSCLC?


The symptoms of non-small cell lung cancer are not specific. Learn more here about the possible symptoms. 

Radiosurgery Followed by Tumor-Treating Fields for NSCLC Brain Metastases

Dr Minesh P Mehta discusses radiosurgery followed by tumor-treating fields for NSCLC brain metastases.

Motivating Stage III NSCLC Patients to Stay on Treatment

Oncology specialists from a lung multidisciplinary team discuss best practices on motivating patients to stay on therapy.

Expert Video Report on Lung Cancer From ASCO 2020

Reporting remotely on findings presented at ASCO 2020 Virtual Meeting, Egbert Smit comments on important and potentially practice changing study results in NSCLC.

Pembrolizumab for Non-Small Cell Lung Cancer Associated Brain Metastases

Dr Sarah B. Goldberg discusses the use of pembrolizumab for non-small cell lung cancer associated brain metastases.

Improving the Staging and Diagnosis of Patients With Stage III/IV Non-Small Cell Lung Cancer

Findings for Pathology and Pulmonary Medicine From a National Quality Survey, presented at the CAP 2020 Virtual Meeting.

Immunotherapy Trial Updates in NSCLC From ESMO 2020

Dr Roy Herbst discusses three abstracts presented at the ESMO 2020 virtual congress, including 5-year overall survival data from the KEYNOTE-024 study evaluating pembrolizumab versus CT in NSCLC...

CITYSCAPE: Tiragolumab Plus Atezolizumab for Non-Small-Cell Lung Cancer


The CITYSCAPE trial is a randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab vs placebo + atezolizumab in patients with PD-L1-selected NSCLC.

ADAURA Results: Adjuvant Osimertinib for EGFRm Non-Small Cell Lung Cancer

Prof Roy Herbst speaks to ecancer about the abstract he presented at the 2020 ASCO Virtual Meeting on the results of the ADAURA trial.

BFAST: High Dose Alectinib for RET-Positive NSCLC

Dr. Nir Peled discusses the safety and efficacy results of high-dose alectinib treatment for patients with treatment naive RET-positive NSCLC in the Blood First Assay Screening Trial.

Phase II CodeBreak 100 trial of Sotorasib in Advanced NSCLC

Outcomes in patients with heavily pre-treated advanced NSCLC are very poor. To address this, the Phase II CodeBreak 100 trial investigated sotorasib, a first-in-class irreversible inhibitor...

NICE Approval: Brigatinib in ALK NSCLC

Dr. Raffaele Califano discusses the recent NICE approval of brigatinib for the treatment of patients with ALK-positive NSCLC who have not been previously treated with an ALK inhibitor.

Use of Liquid Biopsy in Stage IV Non-Small Cell Lung Cancer Patients

Considerations for use of liquid biopsy in Stage IV NSCLC are discussed by oncology specialists from a lung multidisciplinary team.

Key NSCLC Updates

Jarushka Naidoo outlines key NSCLC updates from the virtual Gathering Around Cancer 2020 Irish meeting, including novel targeted therapies designed for EGFR, ALK...

ESMO 2020 Highlights on Durability of Clinical Benefit and Biomarkers With AMG510 in NSCLC

David Hong reports on key results from ESMO Virtual Congress 2020 on 1257O: Durability of clinical benefit and biomarkers in patients with advanced NSCLC treated with AMG 510.

Combining Immuno-Oncology and Standard Chemo in the Treatment of NSCLC

Dr. Solange Peters provides a summation of the Keynote-189, CheckMate 9LA, and CheckMate 227 clinical trials, and what these findings mean for the treatment of patients with NSCLC.

Oncology Learning Network
Researchers Demonstrate Promising Efficacy of Lorlatinib in Patients With ALK+ NSCLC

Dr. David Carbone offers his perspective on 2 clinical trials that evaluated the use of lorlatinib in patients with ALK-positive non–small-cell lung cancer.

Oncology Learning Network
METex14 SAs (MET Exon 14 Skipping Alterations) in Non-Small Cell Lung Cancer

Dr. Mark Awad speaks to ecancer in an online interview for the ASCO virtual meeting 2020 about METex14 SAs as oncogenic drivers in non-small cell lung cancer.

The Latest in Non-Small Cell Lung Cancer Pathology

Profs Benjamin Besse and Albrecht Stenzinger speak to ecancer about the current landscape of NSCLC pathology, and the current state of play for the interaction...

Counteracting Non-Small Cell Lung Cancer’s Resistance to Radiation Therapy


Li, et al. “CLPTM1L induces estrogen receptor β signaling-mediated radioresistance in non-small cell lung cancer cells.”

ASCO20 - New Research in Non-Small Cell Lung Cancer

Dr Roy Herbst discusses data presented at the ASCO20 Virtual Scientific Program highlighting some of the latest research in NSCLC the most common type of lung cancer.

The Potential of KRAS Inhibitors for Non-Small-Cell Lung Cancer


Prof Reinhard Büttner speaks to ecancer about a pathologist's perspective on targeting KRAS-driven oncogenic signalling in NSCLC.

Why Brigatinib Was Approved to Treat ALK+ Non-Small Cell Lung Cancer?


Dr Ross Camidge explains the clinical trial, the phase 3 ALTA 1L trial, that led to the approval of Brigatinib as a first-line therapy to treat ALK+ metastatic NSCLC.

Personalized Medicine, Genetic Testing Could Shape the Future of Non-Small Cell Lung Cancer

According to Dr. Nathan A.

LungART: Radiotherapy after Surgery for Patients with Non Small Cell Lung Cancer

Dr Cécile Le Péchoux talked to ecancer online about the LungART trial presented at the ESMO 2020 virtual meeting this year.

COVID-19: Management of Non-Small Cell Lung Cancer Patients During the Coronavirus Pandemic


Dr Heather Wakelee from the University of Stanford speaks to ecancer about the treatment of NSCLC patients during the COVID-19 pandemic.

Lung Cancer Immunotherapy with Dr. Leena Gandhi

Dr. Leena Gandhi leads a discussion on the latest immunotherapy for lung cancer patients.

PD-L1 Testing in Non-Small Cell Lung Carcinoma

Dr. Anja Roden discusses the role of PD-L1 interaction in the immune system, challenges with PD-L1 testing, and current PD-L1 testing in NSCLC.

PIONeeR: Understanding PD-L1 resistances in non-small cell lung cancer

Prof. Fabrice Barlesi speaks to ecancer about the ESMO 2020 virtual congress concerning a first analysis of the PIONeeR study.

Management of Non-Small Cell Lung Cancer


Prof C S Pramesh presents a talk on 'Management of Non-Small Cell Lung Cancer' at the Choosing Wisely: Value Added Cancer Care for India event in New Delhi.

Presentation of Stage III Non–Small Cell Lung Cancer


Dr. Stephen Liu presents the case of a 62-year-old man with stage III non–small cell lung cancer and provides insight into management and prognosis.

Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer

Dr Julia Rotow talks to ecancer in an online interview for the ASCO virtual meeting 2020 about using concurrent osimertinib plus gefitinib for treating EGFR-mutated NSCLC.

ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer

Prof Benjamin Besse and Dr Alex Spira discuss the latest developments in EGFR-mutated NSCLC.

Immunotherapy Treatments for Non-Small Cell Lung Cancer

This animation provides an overview of several immunotherapy treatments that have been approved for NSCLC.


source list reference